Reviewing Interpace Diagnostics Group (IDXG) & Ituran Location and Control (ITRN)
Interpace Diagnostics Group (NASDAQ: IDXG) and Ituran Location and Control (NASDAQ:ITRN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.
This is a breakdown of recent recommendations and price targets for Interpace Diagnostics Group and Ituran Location and Control, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Interpace Diagnostics Group||0||0||1||0||3.00|
|Ituran Location and Control||0||0||1||0||3.00|
Interpace Diagnostics Group presently has a consensus target price of $5.00, indicating a potential upside of 290.63%. Ituran Location and Control has a consensus target price of $31.00, indicating a potential downside of 10.92%. Given Interpace Diagnostics Group’s higher possible upside, equities analysts plainly believe Interpace Diagnostics Group is more favorable than Ituran Location and Control.
This table compares Interpace Diagnostics Group and Ituran Location and Control’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Interpace Diagnostics Group||-37.08%||-32.06%||-11.22%|
|Ituran Location and Control||18.67%||36.12%||22.00%|
Institutional & Insider Ownership
7.2% of Interpace Diagnostics Group shares are owned by institutional investors. Comparatively, 51.6% of Ituran Location and Control shares are owned by institutional investors. 0.7% of Interpace Diagnostics Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Interpace Diagnostics Group and Ituran Location and Control’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Interpace Diagnostics Group||$13.09 million||2.17||-$8.33 million||($0.96)||-1.33|
|Ituran Location and Control||$199.57 million||3.66||$32.13 million||$1.95||17.85|
Ituran Location and Control has higher revenue and earnings than Interpace Diagnostics Group. Interpace Diagnostics Group is trading at a lower price-to-earnings ratio than Ituran Location and Control, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Interpace Diagnostics Group has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Ituran Location and Control has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.
Ituran Location and Control pays an annual dividend of $0.96 per share and has a dividend yield of 2.8%. Interpace Diagnostics Group does not pay a dividend. Ituran Location and Control pays out 49.2% of its earnings in the form of a dividend.
Ituran Location and Control beats Interpace Diagnostics Group on 9 of the 13 factors compared between the two stocks.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.
About Ituran Location and Control
Ituran Location and Control Ltd. is a provider of location-based services, consisting of stolen vehicle recovery (SVR), fleet management services and other tracking services. The Company also provides wireless communication products used in connection with its location-based services and various other applications. Its operations consist of two segments: location-based services and wireless communications products. Its location-based services segment consists of its SVR and tracking services, fleet management and value-added services consisted of personal locater services and concierge services. Its wireless communications products segment consists of short and medium range two-way machine-to-machine wireless communications products that are used for various applications, including automatic vehicle location (AVL) and automatic vehicle identification. It primarily provides its services, as well as sells and leases its products in Israel, Brazil, Argentina and the United States.
Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.